TecMed, Inc.

TecMed's patented perioperative and critical care Sentinel Real-Time Continuous Glucose Monitoring (RT-CGM) measurement platform enables automated, real-time, low-cost glucose measurement with demonstrated industry best accuracy of +/ - 6% . The technology uses optically-based direct measurement of glucose versus existing 2nd and 3rd order measurements of products from enzymatic reactions that are further adjusted with predictive algorithms. Drawing automatically from a patient's IV, no finger pricks or costly nurse time is required, allowing hospitals the opportunity to show net positive profit on glucose measurement. TecMed, Inc. is a privately held IP company focused on the creation, development and outlicensing of IP for medical devices. TecMed's eminently accurate, automated, real-time and cost-effective blood glucose measurement and monitoring technologies are now ready for licensing. Our staff is comprised of notable individuals with many years of real-world experience and success, leading to a team with intense focus and commitment. TecMed's current focus is the creation of business relationships for the commercialization of our IP, which includes significant technological "know how".

• Employees 6
• Annual Revenue $19948000